The global liposomal doxorubicin market size reached US$ 1.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 1.6 Billion by 2027, exhibiting a growth rate (CAGR) of 6.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.
Liposomal Doxorubicin Market Trends:
The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global liposomal doxorubicin market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product and application.
Breakup by Product:
Breakup by Application:
- Bone Sarcoma
- Breast Cancer
- Endometrial Cancer
- Kidney Cancer
- Multiple Myeloma
- Kaposi Sarcoma
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.
|Base Year of the Analysis
||Product, Application, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global liposomal doxorubicin market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global liposomal doxorubicin market and who are the key players?
- What is the degree of competition in the industry?